Loading...
ICVX logo

Icosavax, Inc.NasdaqGS:ICVX Stock Report

Market Cap US$777.8m
Share Price
n/a
US$17.91
n/aintrinsic discount
1Y68.8%
7D-0.6%
Portfolio Value
​
View

Icosavax, Inc.

NasdaqGS:ICVX Stock Report

Market Cap: US$777.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Icosavax (ICVX) Stock Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. More details

ICVX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months


ICVX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Icosavax, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Icosavax
Historical stock prices
Current Share PriceUS$15.31
52 Week HighUS$16.11
52 Week LowUS$4.75
Beta1.28
1 Month Change-0.78%
3 Month Change50.84%
1 Year Change68.80%
3 Year Changen/a
5 Year Changen/a
Change since IPO-56.22%

Recent News & Updates

Recent updates

Analysis Article • Jul 04

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 10

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 18

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 15

Icosavax GAAP EPS of -$0.57

Icosavax press release (NASDAQ:ICVX): Q2 GAAP EPS of -$0.57. Cash and cash equivalents, restricted cash, and short-term investments of $243.9M at end 2Q 2022.
Seeking Alpha • Jul 28

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax (NASDAQ:ICVX) will select a bivalent COVID-19 vaccine to move forward with in 2023 following an investigation into its monovalent COVID vaccine IVX-411. Phase 1/2b topline data for IVX-411 showed an immunologic response that was inconsistent with expectations. A company investigation found that the reduced efficacy was antigen-specific, adding that there are no indications there are issues with the company's virus-like particles technology or other vaccines. In the near-term, by the end of 2022, Icosavax (ICVX) expect to begin a Phase 1 trial IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) bivalent vaccine. Also, 6-month immunogenicity data from a phase 1b extension study for monovalent RSV vaccine IVX-121 is expected by early 2023. In late June, Icosavax shares fell after releasing top-line phase 1 data on IVX-121.
Analysis Article • Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 24

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 29

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ICVXUS BiotechsUS Market
7D-0.6%-4.9%-1.0%
1Y68.8%28.1%23.3%

Return vs Industry: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: ICVX exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement15.1%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: ICVX's share price has been volatile over the past 3 months.

Volatility Over Time: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201760Adam Simpsonicosavax.com

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

Icosavax, Inc. Fundamentals Summary

How do Icosavax's earnings and revenue compare to its market cap?
ICVX fundamental statistics
Market capUS$777.79m
Earnings (TTM)-US$96.71m
Revenue (TTM)n/a
0.0x
P/S Ratio
-8.0x
P/E Ratio

Is ICVX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICVX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$70.04m
Gross Profit-US$70.04m
Other ExpensesUS$26.67m
Earnings-US$96.71m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.90
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ICVX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/19 08:23
End of Day Share Price 2024/02/16 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Icosavax, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerEvercore ISI
Seamus FernandezGuggenheim Securities, LLC
Roger SongJefferies LLC